Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILT-123 with TILs and lymphodepleting chemotherapy in metastatic melanoma
NCT06961786Phase 1Active, not recruiting
- Sponsor
- TILT Biotherapeutics
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ad5/3-E2F-D24 in melanoma, sponsored by TILT Biotherapeutics. Primary endpoints: Number of Participants with any (serious and non-serious) Adverse Events at 78 days, Number of Participants with abnormal laboratory values at 78 days and 2 more. Started Jun 2025; status: active, not recruiting.
02
Drugs
Ad5/3-E2F-D24
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06961786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961786.